exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088182 RNA Name: hsa-miR-33b-5p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 17813897 End Site(bp): 17813916 External Links: hsa-miR-33b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ADCY9 chr16 3953387 4116442 - AFF4 chr5 132875395 132963634 - BTBD7 chr14 93237550 93333092 - CERK chr22 46684410 46738252 - CROT chr7 87345681 87399795 + DDX5 chr17 64498254 64508199 - E2F3 chr6 20401879 20493714 + ECHDC1 chr6 127288712 127343609 - EIF5A2 chr3 170888418 170908644 - IGF1R chr15 98648539 98964530 + IRS2 chr13 109752695 109786583 - MAPK1IP1L chr14 55051647 55070194 + MAPK6 chr15 51952106 52067375 + MTHFD2 chr2 74198610 74217565 + MYO19 chr17 36495633 36543435 - NAA15 chr4 139301505 139420033 + NFAT5 chr16 69565094 69704666 + PIM1 chr6 37170152 37175428 + RBM33 chr7 155644451 155781485 + RCAN1 chr21 34513142 34615113 - ROBO1 chr3 78597239 79767998 - SLC39A8 chr4 102251041 102431258 - SULF2 chr20 47656348 47786616 - TNPO1 chr5 72816312 72916733 + TPM1 chr15 63042632 63071915 + UBN2 chr7 139230356 139308236 + WDFY3 chr4 84669610 84966391 - XRN1 chr3 142306607 142448062 - ZFYVE16 chr5 80408013 80483379 + ZNF148 chr3 125225561 125375354 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000284 chr11 33307958 33309057 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC023509.1 chr12 53441741 53467528 + DANCR chr4 52712404 52720351 + FGD5-AS1 chr3 14920347 14948424 - MCF2L-AS1 chr13 112967484 112968824 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.